IP Library › Granted Patent US 12,458,217
Granted Patent B2
US 12,458,217 · App. 17/427,202 · Granted Nov 4, 2025

Light emitting device and medical device using same

Inventors: Takeshi Abe (Osaka, JP); Shozo Oshio (Osaka, JP); Mitsuru Nitta (Kyoto, JP)
Assignee: Panasonic Intellectual Property Management Co., Ltd.
A61B1/0653A61B1/0638A61B1/0669F21V9/38H01S5/0087H10H20/8513F21Y2115/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,217
App. No.
17/427,202
Granted
Nov 4, 2025
Kind
B2
Abstract

A light emitting device is a light emitting device for use in a photodynamic therapy. The light emitting device includes: a solid-state light-emitting element that emits primary light in which an energy density is 0.5 W/mm 2 or more; and a wavelength converter including a first phosphor that emits first wavelength-converted light. The first wavelength-converted light has a light component across at least a whole of a wavelength range of 700 nm or more and less than 800 nm. Energy of fluorescence emitted from the wavelength converter is 100 mW or more. A medical device includes the light emitting device.

Claims (14)

1 . A light emitting device, comprising:

a solid-state light-emitting element that emits primary light in which an energy density is 0.5 W/mm 2 or more; and

a wavelength converter including a single phosphor, wherein the single phosphor emits first wavelength-converted light,

wherein the single phosphor consists of a crystal structure of garnet,

wherein the first wavelength-converted light has a light component across at least a whole of a wavelength range of 700 nm or more and less than 800 nm,

wherein the first wavelength-converted light has a fluorescence peak within a wavelength range of 700 nm to 1000 nm,

wherein energy of fluorescence emitted from the wavelength converter is 100 mW or more, and

wherein the light emitting device is used for a photodynamic therapy.

2 . The light emitting device according to claim 1 , wherein the first wavelength-converted light has the light component across a whole of a wavelength range of 600 nm or more and 800 nm or less.

3 . The light emitting device according to claim 1 , wherein the single phosphor includes at least one of a Eu 2+ -activated phosphor or a Ce 3+ -activated phosphor.

4 . The light emitting device according to claim 1 , wherein the single phosphor includes a Cr 3+ -activated phosphor.

5 . The light emitting device according to claim 1 , wherein the solid-state light-emitting element radiates the primary light having a maximum intensity value within a wavelength range of 430 nm or more and 480 nm or less, 500 nm or more and 560 nm or less, or 600 nm or more and 700 nm or less.

6 . A medical device comprising the light emitting device according to claim 1 .

7 . The light emitting device according to claim 1 , wherein, in the first wavelength-converted light, a 1/e fluorescence lifetime is 20 ns or more and 1000 μs or less.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2021
From: ABE, TAKESHI; OSHIO, SHOZO; NITTA, MITSURU
To: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
Reel/Frame 058106/0554 →
Priority Claims (1)
JP 2019-017797 · Feb 4, 2019 · national
Continuity (1)
Related Publication 20230105882A1 · Apr 6, 2023
References Cited (42)
US 6385221B1 · Neuberger · 2002 [cited by applicant]
US 6607384B1 · Nakanishi · 2003 [cited by examiner]
US 10411170B2 · Tragl et al. · 2019 [cited by applicant]
US 20060198418A1 · Hama et al. · 2006 [cited by applicant]
US 20090167149A1 · Ito · 2009 [cited by applicant]
US 20110248624A1 · Kishimoto · 2011 [cited by examiner]
US 20130030264A1 · Gopalakrishnan · 2013 [cited by examiner]
US 20130147343A1 · Won · 2013 [cited by examiner]
US 20140003074A1 · Kishimoto · 2014 [cited by examiner]
US 20140022810A1 · Ito et al. · 2014 [cited by applicant]
US 20150055358A1 · Nitta et al. · 2015 [cited by applicant]
US 20150346360A1 · Yoshikawa · 2015 [cited by examiner]
US 20170051883A1 · Raring · 2017 [cited by examiner]
US 20170156187A1 · Yamashita · 2017 [cited by examiner]
US 20180216002A1 · Nagao et al. · 2018 [cited by applicant]
US 20180346808A1 · Nitta et al. · 2018 [cited by applicant]
US 20180358514A1 · Tragl et al. · 2018 [cited by applicant]
US 20190088832A1 · Onuma et al. · 2019 [cited by applicant]
US 20190194539A1 · Rajendran · 2019 [cited by examiner]
US 20200227598A1 · Schmidt · 2020 [cited by examiner]
US 20210113076A1 · Abe et al. · 2021 [cited by applicant]
CN 112110729A · 2020 [cited by examiner]
EP 3480280A1 · 2019 [cited by applicant]
EP 3904488A1 · 2021 [cited by applicant]
JP 2006253099A · 2006 [cited by applicant]
JP 2009153712A · 2009 [cited by applicant]
JP 2012209190A · 2012 [cited by applicant]
JP 2015061902A · 2015 [cited by applicant]
JP 2016119999A1 · 2016 [cited by applicant]
JP 2017066245A · 2017 [cited by examiner]
JP 2018518046A · 2018 [cited by applicant]
JP 2018203983A · 2018 [cited by applicant]
WO 2012069542A1 · 2012 [cited by applicant]
WO 2017164214A1 · 2017 [cited by applicant]
WO 2018008171A1 · 2018 [cited by applicant]
WO 2018008283A1 · 2018 [cited by applicant]
WO WO2019063297A1 · 2019 [cited by examiner]
WO 2019187637A1 · 2019 [cited by applicant]
English language translation of JP-2017066245-A, Kamata K, Apr. 6, 2017. [cited by examiner]
Extended European Search Report for corresponding EP Application No. 20752368.9 issued Mar. 3, 2022. [cited by applicant]
International Search Report and Written Opinion of the ISA for corresponding PCT International Application PCT/JP2020/002680, with partial English language translation, 2020. [cited by applicant]
Chinese Search Report for corresponding Application No. 202080012464.8 issued May 31, 2024, with English translation. [cited by applicant]